

1 Impaired cellular immunity to SARS-CoV-2 in severe COVID-19

2 patients

3

4 Ling Ni^{1,2,*}, Meng-Li Cheng^{3,4,*}, Hui Zhao^{4,*}, Yu Feng¹, Jingyuan Liu⁵, Fang Ye⁶,

5 Qing Ye⁴, Gengzhen Zhu¹, Xiaoli Li¹, Pengzhi Wang¹, Jing Shao¹, Yong-Qiang

6 Deng⁴, Peng Wei¹, Fang Chen⁷, Cheng-Feng Qin⁴, Guoqing Wang³, Fan Li^{3,8,#},

7 Hui Zeng^{5,#}, Chen Dong^{1,2,9,10,#}

8

9 1. Institute for Immunology and School of Medicine, Tsinghua University, Beijing

10 100084, China

11 2. Center for Human Disease Immuno-monitoring, Beijing Friendship Hospital,

12 Beijing 100050, China

13 3. College of Basic Medical Science, Jilin University, Changchun 130021, China

14 4. Department of Virology, State Key Laboratory of Pathogen and Biosecurity,

15 Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences,

16 Beijing 100071, China

17 5. Beijing Ditan Hospital, Capital Medical University, and Beijing Key Laboratory

18 of Emerging Infectious Diseases, Beijing100015, China

19 6. Department of Hematology, Chui Yang Liu Hospital affiliated to Tsinghua

20 University, Beijing 100022, China

21 7. Department of Cardiology, Chui Yang Liu Hospital affiliated to Tsinghua

22 University, Beijing100022, China

23 8. China-Japan Union Hospital, Jilin University, Changchun 130033, China

24 9. Beijing Key Lab for Immunological Research on Chronic Diseases, Beijing

25 100084, China

1 10. Lead Contact

2 *These authors contributed equally to this work.

3

4 #To whom correspondence should be addressed: Chen Dong,

5 chendong@tsinghua.edu.cn; or zenghui@ccmu.edu.cn; Fan Li, lifan@jlu.edu.cn

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

1 **SUMMARY**

2
3 The World Health Organization has declared SARS-CoV-2 virus outbreak a
4 world-wide pandemic. Individuals infected by the virus exhibited different degrees of
5 symptoms, the basis of which remains largely unclear. Currently, though
6 convalescent individuals have been shown with both cellular and humoral immune
7 responses, there is very limited understanding on the immune responses, especially
8 adaptive immune responses, in patients with severe COVID-19. Here, we examined
9 10 blood samples from COVID-19 patients with acute respiratory distress syndrome
10 (ARDS). The majority of them (70%) mounted SARS-CoV-2-specific humoral
11 immunity with production of neutralizing antibodies. However, compared to healthy
12 controls, the percentages and absolute numbers of both NK cells and CD8⁺ T cells
13 were significantly reduced, accompanied with decreased IFN γ expression in CD4⁺ T
14 cells in peripheral blood from severe patients. Most notably, we failed in detecting
15 SARS-CoV-2-specific IFN γ production by peripheral blood lymphocytes from these
16 patients. Our work thus indicates that COVID-19 patients with severe symptoms are
17 associated with defective cellular immunity, which not only provides insights on
18 understanding the pathogenesis of COVID-19, but also has implications in
19 developing an effective vaccine to SARS-CoV-2.

20

21

22 Keywords: SARS-CoV-2, acute respiratory distress syndrome, adaptive immunity,
23 neutralization antibody, T cells

24

25

26

1 **Introduction**

2 Identified in December, 2019, coronavirus disease 2019 (COVID-19) caused by
3 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Wang et al., 2020a)
4 has become a global public health threat. As of July 17th, 2020, 13,378,853 global
5 cases were confirmed, of which 580,045 patients died
6 ([https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)
7 [reports](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)). The high infection rate and rapid spread make it a world-wide emergency
8 (Di Pierro et al., 2020). However, up to date, there is no specific anti-viral medicine
9 or vaccine available to prevent or treat COVID-19 and the current standard care
10 relies on supportive treatments.

11 Approximately 80% of COVID-19 cases are asymptomatic or manifest mild
12 symptoms resembling simple upper respiration tract infection. The remaining
13 COVID-19 patients show severe or critical symptoms with severe pneumonia and
14 acute respiratory distress syndrome (ARDS) (Gruszecka and Filip, 2020). How the
15 immune system modifies and controls the infection is still not well understood, which
16 may underscore the different degrees of symptoms amongst the population. Several
17 papers were reported on the adaptive immune responses in the recovered mild
18 COVID-19 patients. We detected SARS-CoV-2-specific antibodies and T cells in
19 convalescent individuals (Ni et al., 2020). Grofoni et al also found that ~70% and 100%
20 of COVID-19 convalescent subjects with mild and severe symptoms developed
21 SARS-CoV-2-specific CD8⁺ and CD4⁺ T cells, respectively (Grifoni et al., 2020).
22 However, there is very limited understanding on immune responses in severe
23 COVID-19 patients during hospitalization. In a retrospective study, Chen et al
24 observed that absolute numbers of T lymphocytes, both CD4⁺ and CD8⁺, were
25 markedly lower in severe patients than those in moderate cases (Chen et al., 2020).

1 In contrast to the aforementioned study, Zheng et al did not observe reduced
2 lymphocytes in the severe disease group, but T cells showed elevated exhaustion
3 levels and reduced functional heterogeneity (Zheng et al., 2020). Using megapools
4 of overlapping or prediction-based peptides covering the SARS-CoV-2 proteome,
5 Weiskopf et al found CD4⁺ and CD8⁺ T cells showed activation marker expression in
6 10 out of 10 and 8 out of 10 patients with severe COVID-19 during hospitalization,
7 respectively (Weiskopf et al., 2020). For humoral responses, Lynch et al found that
8 antibody responses were higher in patients with severe than mild disease (Lynch et
9 al., 2020). And high levels of neutralizing antibodies was induced 10 days post onset
10 in both mild and severe patient, which were higher in severe group (Wang et al.,
11 2020b).

12 In order to understand immune responses and the mechanism underlying the
13 pathogenesis of severe COVID-19, we collected blood samples from 10 patients with
14 ARDS, analyzed their cellular and humoral responses specific to SARS-CoV-2, and
15 compared severe and convalescent patients. Our data reveal defective cellular
16 immunity associated with severe COVID-19. This study provides new insights on the
17 precise treatment of COVID-19 patients and evaluation of candidate vaccines.

18

19

1 **Results**

2 **Detection of SARS-CoV-2-specific antibodies in severe COVID-19 subjects**

3 To understand the immune responses to SARS-CoV-2 in severe patients, we
4 studied 10 patients with acute respiratory distress syndrome (ARDS). Their clinical
5 and pathological characteristics are shown in Table 1. All the patients were
6 hospitalized at Beijing Ditan Hospital and showed severe symptoms via CT scan and
7 were positive in SARS-CoV-2 nucleic acid testing. The mean age was 57.5 years
8 and half of them were female. Among them, 8 (80%) showed lymphopenia. As of
9 today, 1 patient (Pt#9) passed away and the remaining ones had recovered and
10 were discharged from hospital. The blood samples were obtained within 20 days
11 post symptom onset and the detail sampling day for each patient was also shown in
12 Table 1. Human AB serum collected from healthy male AB donors in the US
13 (GemCell, CA) was used as a negative control. Additionally, sera from nine healthy
14 donors were obtained before the SARS-CoV-2 outbreak (HD#1-9). 5 additional
15 healthy donors (HD#10-14) without SARS-CoV-2 infection were analyzed in our T
16 cell assays.

17 Using sera from patients and healthy donors, IgG and IgM specific to SARS-
18 CoV-2 NP and S-RBD antigens were analyzed using ELISA assay previously
19 reported (Ni et al., 2020). The individual serum samples were performed by serial
20 dilutions to calculate the area under the curve (AUC) values (Figure 1A). Compared
21 with healthy donors, patients with severe COVID-19 showed significantly elevated
22 anti-NP IgG AUC values (Figure 1B). The AUC values of anti-S-RBD IgG in severe
23 cases were also significantly increased compared to those in healthy controls.
24 Serum NP- and S-RBD-specific IgM antibodies showed significantly higher AUC
25 values in severe COVID-19 patients than in healthy controls (Figure 1B). Notably,

1 patients #1, 4 and 7 did not develop NP- and S-RBD -specific antibody responses,
2 including IgM and IgG. As shown in Figure 1C, anti-NP and S-RBD IgG in severe
3 patients was mainly IgG1 isotype, as in convalescent individuals (Ni et al., 2020). We
4 did not detect IgG2 to either NP or S-RBD proteins (data not shown).

5 In order to understand the pathogenic mechanisms in severe patients, we
6 compared the levels of virus-specific IgG or IgM in these patients with those in
7 convalescent individuals. Serum from one convalescent COVID-19 patient was used
8 as a positive control standard to calculate the antibody titers (relative units) for all
9 samples using non-linear regression interpolations (Grifoni et al., 2020). Of note, we
10 observed no significant differences in anti-NP/S-RBD IgG or IgM between these two
11 groups (Figure 1D).

12 Taken together, these findings indicate that most severe COVID-19 patients
13 mounted IgG and IgM responses specific to SARS-CoV-2 proteins, NP and S-RBD.
14 However, the levels of humoral immune responses varied among the patients.

15

16 **Measurement of neutralizing antibody production in severe COVID-19 subjects**

17 To determine the neutralization capacity in sera from patients with severe
18 COVID-19, we performed pseudovirus particle-based neutralization assay as
19 previously described (Ni et al., 2020). As shown in Figure 2A and 2B, patients #1, 4
20 and 7, did not produce neutralizing antibodies, while patient #3 had a high
21 neutralizing antibody titer (NAT50>1000). Most severe patients (70%) had protective
22 humoral immunity to SARS-CoV-2. Notably, sera from severe patients did not show
23 significantly reduced NAT50 values than convalescent sera (Figure 2C). About 30%
24 of severe patients and 8% of convalescent individuals did not produce neutralizing
25 antibodies, respectively (Figure 2D). Around 40%, 20% and 10% of severe patients

1 showed low (NAT50: 30-500), medium (NAT50: 500-1000) and high (NAT50: >1000)
2 NAT50, respectively, while 50%, 21% and 21% in the convalescent group did.

3 Nonetheless, our results indicate that most severe patients had serum
4 neutralizing antibodies to SARS-CoV-2 infection.

5

6 **Lymphocyte numbers and function in severe COVID-19 subjects**

7 To analyze cellular immune responses to SARS-CoV-2, peripheral blood
8 mononuclear cells (PBMCs) from 10 patients with severe COVID-19 and 5 healthy
9 donors were phenotypically analyzed by flow cytometry (Figure 3A). We did not
10 detect live PBMCs in 3 out of 10 patients (Pts# 3, 4 and 5), possibly due to technical
11 issues during cryopreservation. Compared to healthy donors, there was a significant
12 decrease in the percentages of NK cells in the severe patients, but similar
13 frequencies of NKT cells (Figure 3B). Although there was a trend towards increased
14 frequencies of T cells (CD3⁺CD56⁻) in the patient blood, the absolute numbers of T
15 cells were significantly decreased compared to those in blood from healthy controls
16 (Figure 3C). Notably, the percentages and absolute numbers of CD8⁺ T cells were
17 reduced dramatically, while the frequency of CD4⁺ T cells was elevated compared
18 with those in healthy donors. As a result, the CD4:CD8 ratios were significantly
19 higher in severe patients than in the healthy donors (6.7 ± 1.3 in COVID-19 vs $2.5 \pm$
20 0.3 in HD, $P=0.0226$) (Figure 3B). Thus, the severe patients exhibited reduced
21 cytotoxic lymphocytes, both NK and CD8⁺ T cells.

22 To further assess the function of the T cells in the severe patients, we stimulated
23 T cells with phorbol myristate acetate (PMA) and ionomycin and then measured
24 cytokine production. As shown in Figure 4A and 4B, CD4⁺ T cells from severe
25 patients expressed significantly lower levels of IFN γ than those from healthy donors.

1 We observed no apparent difference in the frequencies of TNF α -expressing CD4 $^+$ T
2 cells, but significantly reduced percentages of IFN γ^+ TNF α^+ T cells (Figure 4C and
3 4D), consistent with a published report (Chen et al., 2020). Only 2 out of 7 patients
4 had detectable IL-17A $^+$ CD4 $^+$ T cells, which expressed TNF α , but not IFN γ (Figure
5 4D).

6 Despite the decreased frequencies of CD8 $^+$ T cells in PBMCs from the patients,
7 these CD8 $^+$ T cells expressed similar levels of cytokines IFN γ and TNF α as the ones
8 from healthy donors (Figure 4E and 4F). In addition, similar frequencies of
9 IFN γ^+ TNF α^+ CD8 $^+$ T cells were found in severe patients and healthy donors (Figure
10 4G).

11 We also evaluated capacities of cytokine production in CD3 $^+$ cells, likely NK cells.
12 As shown in Figure 4H, these cells in severe patients expressed significantly
13 reduced levels of IFN γ and TNF α than those in healthy donors. We did not observe
14 significant difference in terms of the frequency of IFN γ^+ TNF α^+ cells between these
15 two groups (Figure 4H).

16

17 **Cellular immune responses to SARS-CoV-2 in severe COVID-19 subjects**

18 To further measure virus-specific cellular immunity, we treated PBMCs with
19 recombinant NP, S-RBD and S proteins, followed by IFN γ ELISpot analysis. As
20 shown in Figure 5A, the absolute numbers of T cells produced IFN γ in response to
21 anti-CD3 were decreased dramatically in PBMCs from severe patients than those
22 from healthy donors. More strikingly, we did not detect any SARS-CoV-2-specific T
23 cells in all the tested severe patients, whereas one out of ten T cells could secret
24 IFN γ after exposure to NP protein in convalescent individuals (Figure 5B).

1 Thus, T cells in the severe COVID-19 patients failed in developing cellular
2 immunity to SARS-CoV-2.

3

4

1 **Discussion**

2 In this study, we characterized humoral and cellular immunity in severe COVID-
3 19 patients during hospitalization. Although most patients developed anti-SARS-
4 CoV-2 IgG and IgM responses, humoral immune responses varied widely among the
5 patients. The percentages and absolute numbers of both NK cells and CD8⁺ T cells
6 were significantly reduced, accompanied with decreased Th1 cell response in
7 peripheral blood from severe patients. Most notably, we failed in SARS-CoV-2-
8 specific IFN γ production in these patients.

9 In this study, most severe patients had reduced Th1 cell responses, consistent
10 with the published report (Chen et al., 2020). Another report showed that peripheral
11 blood of a severe COVID-19 patient had a strikingly high number of CCR6⁺ Th17
12 cells (Xu et al., 2020). In addition, several papers proposed use of therapies directed
13 at Th17 cells and IL-17A signaling in treating COVID-19 patients (De Biasi et al.,
14 2020; Orlov et al., 2020; Wu and Yang, 2020). However, we observed no significant
15 Th17 cell responses in most of the severe patients (5/7) with only one patient
16 showing elevated IL-17A expression. Several possibilities may account for the
17 discrepancy. One is different markers used for defining Th17 cells. The above-
18 mentioned paper used CCR6 on CD4⁺ T cells to define Th17 cells, whereas we used
19 IL-17A expression in CD4⁺ T cells. Another is different patient cohort and disease
20 severity. Sample timing during disease course is another possibility, since T cell
21 responses are dynamic. Given not all the severe COVID-19 patients had increased
22 IL-17A expression, one may not want to treat all patients with IL-17A inhibitors.

23 5 healthy donors (HD#10-14) with a mean age of 29.4 years were included in our
24 T cell assays, which are not age-matched with severe patients with a mean age of
25 57 years. Compared to healthy controls, severe patients showed reduced

1 percentages of CD8⁺ T cells and IFN γ -expressing CD4⁺ T cells. Previously, Carr et al
2 found that frequencies of Th1 and CD8⁺ T cells were enhanced with age (Carr et al.,
3 2016). Thus, the differences we observed between healthy controls and severe
4 patients were unlikely caused by age.

5 In our study, antigens-specific IFN γ expression was not detected in severe
6 patients, in contrast to the report (Weiskopf et al., 2020). We used antigen-mediated
7 IFN γ ELISpot analysis to detect antigen-specific T cells, while the other group used T
8 cell receptor-dependent activation marker assay in measuring the expression of
9 CD137 and CD69. Since AIM assay did not measure effector function by T cells, it is
10 possible that virus-specific T cells are “exhausted”. Different patient cohort and
11 sample timing may account for the different results.

12 In summary, we detected anti-SARS-CoV-2 antibody responses in most severe
13 cases, while impaired cellular responses were observed in all severe COVID-19
14 patients. Our results thus provide insight in the pathogenesis of severe COVID-19.
15 They suggest that induction of cellular immunity is vital in controlling SARS-CoV-2
16 infection, which also has implications in development of an effective vaccine.

17

18

1 **ACKNOWLEDGEMENT**

2 We thank Weijin Huang and Jianhui Nie from the National Institutes for Food and
3 Drug Control for sharing the plasmids for pseudovirus package. This work was
4 supported in part by grants from the National Key Research and Development
5 Program of China (2016YFC0906200 to CD, 2016YFC130390 to LN , and
6 2020YFA0707800 to XW), Natural Science Foundation of China (31991173,
7 31821003 and 31991170 to CD), Beijing Municipal Science and Technology
8 (Z181100001318007, Z181100006318015 and Z171100000417005 to C.D.),
9 Zhejiang University Foundation (2020XGZX014 to CD), Tsinghua University (to CD)
10 and Science and Technology Development Plan Project of Jilin Province
11 (20200901007SF to F.L.).

12

13 **AUTHOR CONTRIBUTIONS**

14 L.N. and C.D. designed the research and analyzed the data. Y.F. and F.C.
15 collected clinical specimens with mild COVID-19; J.L. and H.Z. collected clinical
16 specimens with severe COVID-19; Y.D., X.L. and Q.Y. did most of the experiments
17 at a P3 laboratory. M.C., Y.F., H.Z., Q.Y., Z.G., L.X., P. W., S.J. and D.Y. performed
18 some experiments or prepared key reagents; L.N. and C.D. analyzed the results; L.N.
19 and C.D. wrote the manuscript.

20

21 **Conflict of interest**

22 The authors declare that there are no conflicts of interest to disclose.

23

24

25

26

27

1 **Figure legends**

2

3 **Figure 1. Presence of SARS-CoV-2 NP- and S-RBD-specific antibodies in**
4 **severe COVID-19 patients.**

5 (A) Titration of individual serum samples. (B) Data from the same experiments as (A)
6 were presented as area under curve (AUC). (C) IgG isotypes of 10 COVID-19
7 patients to recombinant NP and S-RBD. (D) Serum ELISA titers to NP and S-RBD in
8 sera from convalescent individuals (n=14) and severe patients (n=10). The
9 experiment was performed in duplicates. Data are presented as Mean \pm SEM. NP,
10 nucleocapsid protein. S-RBD, receptor binding domain of spike protein. HD, healthy
11 donor. Pt, patient. AUC, area under curve. HD#1-9, the sera were collected before
12 SARS-CoV-2 outbreak. *P<0.05, 0.05<**P<0.001, ***P<0.001. ns, not significant.

13

14 **Figure 2. Measurement of neutralizing antibody titers in severe COVID-19**
15 **cases.**

16 (A) Neutralizing curves of 10 COVID-19 patients measured by pseudovirus-based
17 assay. The experiment with patients was performed in duplicates. (B) Neutralizing
18 antibody titers of 10 severe COVID-19 patients. (C) Comparison of NAT50 between
19 convalescent subjects (n=14) and severe patients (n=10). Data are presented as
20 Mean \pm SEM. (D) Pie plot showing NAT50 range in severe and convalescent
21 patients. HD, healthy donor (HD#10-14). Pt, patient. NAT50, neutralizing antibody
22 titers. *P<0.05, 0.05<**P<0.001, ***P<0.001. ns, not significant.

23

24 **Figure 3. Phenotypic analysis of blood lymphocytes in severe COVID-19**
25 **patients.**

1 (A) Phenotypic analysis of PBMCs from one representative COVID-19 patient. (B)
2 Summarized data on the frequencies of different immune cell subsets in COVID-19
3 patients and the ratio of CD4:CD8 T cells. (C) Summarized data on the absolute
4 numbers of different immune cell subsets in COVID-19 patients. HD, healthy donors
5 (HD#10-14); Pt, patients (n=7). Data are presented as Mean \pm SEM. *P<0.05,
6 0.05<**P<0.001, ***P<0.001. ns, not significant.

7

8 **Figure 4. Cellular functionality of T cells in severe COVID-19 cases.**

9 (A) Intracellular cytokine staining of CD3⁺CD56⁻CD8⁻ T cells. (B) Summarized data
10 on the frequencies of cytokine-producing CD3⁺CD56⁻CD8⁻ T cells as indicated. (C)
11 Representative FACS plots showing polyfunctional CD3⁺CD56⁻CD8⁻ T cells. (D)
12 Summarized data on the frequencies of polyfunctional CD3⁺CD56⁻CD8⁻ T cells as
13 indicated. (E) Intracellular cytokine staining of CD3⁺CD56⁻CD8⁺ T cells. (F)
14 Summarized data on the frequencies of cytokine-producing CD3⁺CD56⁻CD8⁺ T cells
15 as indicated. (G) Summarized data on the frequencies of polyfunctional CD3⁺CD56⁻
16 CD8⁺ T cells as indicated. (H) Summarized data on the frequencies of cytokine-
17 producing CD3⁻ cells as indicated. HD, healthy donors (HD#10-14); Pt, patients
18 (n=7). Data are presented as Mean \pm SEM. *P<0.05, 0.05<**P<0.001, ***P<0.001.
19 ns, not significant.

20

21 **Figure 5. T cell responses to recombinant SARS-CoV-2 proteins in COVID-19**
22 **patients.**

23 (A) IFN γ ELISpot analysis of COVID-19 patients to anti-CD3 antibody. HD, healthy
24 donors (HD#10-14); Pt, patients (n=7). The experiment with patients was performed
25 in duplicates. (B) The ratios of IFN γ -producing T cells in response to NP or anti-CD3

1 stimulation in both convalescent (n=14) and severe (n=7) patients. Data are
2 presented as Mean \pm SEM. *P<0.05, 0.05<**P<0.001, ***P<0.001.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 Reference

- 2 Carr, E.J., Dooley, J., Garcia-Perez, J.E., Lagou, V., Lee, J.C., Wouters, C., Meyts, I., Goris, A.,
3 Boeckstaens, G., Linterman, M.A., and Liston, A. (2016). The cellular composition of the
4 human immune system is shaped by age and cohabitation. *Nat Immunol* 17, 461-468.
- 5 Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H.,
6 *et al.* (2020). Clinical and immunological features of severe and moderate coronavirus
7 disease 2019. *J Clin Invest* 130, 2620-2629.
- 8 De Biasi, S., Meschiari, M., Gibellini, L., Bellinazzi, C., Borella, R., Fidanza, L., Gozzi, L.,
9 Iannone, A., Lo Tartaro, D., Mattioli, M., *et al.* (2020). Marked T cell activation, senescence,
10 exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. *Nat Commun*
11 11, 3434.
- 12 Di Pierro, F., Bertuccioli, A., and Cavecchia, I. (2020). Possible therapeutic role of a highly
13 standardized mixture of active compounds derived from cultured *Lentinula edodes* mycelia
14 (AHCC) in patients infected with 2019 novel coronavirus. *Minerva Gastroenterol Dietol*.
- 15 Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R., Rawlings,
16 S.A., Sutherland, A., Premkumar, L., Jardi, R.S., *et al.* (2020). Targets of T Cell Responses to
17 SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell*.
- 18 Gruszecka, J., and Filip, R. (2020). Preliminary information on prevention of infections
19 caused by SARS-COV-2 virus in endoscopic laboratories. *Ann Agric Environ Med* 27, 171-174.
- 20 Lynch, K.L., Whitman, J.D., Lacanienta, N.P., Beckerdite, E.W., Kastner, S.A., Shy, B.R.,
21 Goldgof, G.M., Levine, A.G., Bapat, S.P., Stramer, S.L., *et al.* (2020). Magnitude and kinetics
22 of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. *Clin Infect*
23 *Dis*.
- 24 Ni, L., Ye, F., Cheng, M.L., Feng, Y., Deng, Y.Q., Zhao, H., Wei, P., Ge, J., Gou, M., Li, X., *et al.*
25 (2020). Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19
26 Convalescent Individuals. *Immunity* 52, 971-977 e973.
- 27 Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., *et al.*
28 (2020). Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.
29 *Emerg Microbes Infect* 9, 680-686.
- 30 Orlov, M., Wander, P.L., Morrell, E.D., Mikacenic, C., and Wurfel, M.M. (2020). A Case for
31 Targeting Th17 Cells and IL-17A in SARS-CoV-2 Infections. *J Immunol*.
- 32 Wang, C., Horby, P.W., Hayden, F.G., and Gao, G.F. (2020a). A novel coronavirus outbreak of
33 global health concern. *Lancet* 395, 470-473.
- 34 Wang, Y., Zhang, L., Sang, L., Ye, F., Ruan, S., Zhong, B., Song, T., Alshukairi, A.N., Chen, R.,
35 Zhang, Z., *et al.* (2020b). Kinetics of viral load and antibody response in relation to COVID-19
36 severity. *J Clin Invest*.
- 37 Weiskopf, D., Schmitz, K.S., Raadsen, M.P., Grifoni, A., Okba, N.M.A., Endeman, H., van den
38 Akker, J.P.C., Molenkamp, R., Koopmans, M.P.G., van Gorp, E.C.M., *et al.* (2020). Phenotype
39 and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory
40 distress syndrome. *Sci Immunol* 5.
- 41 Wu, D., and Yang, X.O. (2020). TH17 responses in cytokine storm of COVID-19: An emerging
42 target of JAK2 inhibitor Fedratinib. *J Microbiol Immunol Infect* 53, 368-370.
- 43 Xie, S., Huang, J., Qiao, Q., Zang, W., Hong, S., Tan, H., Dong, C., Yang, Z., and Ni, L. (2018).
44 Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma
45 tumors. *Cancer Immunol Immunother* 67, 1685-1694.

1 Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., *et al.*
2 (2020). Pathological findings of COVID-19 associated with acute respiratory distress
3 syndrome. *Lancet Respir Med* 8, 420-422.
4 Zheng, H.Y., Zhang, M., Yang, C.X., Zhang, N., Wang, X.C., Yang, X.P., Dong, X.Q., and Zheng,
5 Y.T. (2020). Elevated exhaustion levels and reduced functional diversity of T cells in
6 peripheral blood may predict severe progression in COVID-19 patients. *Cell Mol Immunol* 17,
7 541-543.

8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

1 STAR METHODS

2 KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Anti-CD45 (clone H130)	BioLegend	Cat# 304028
Anti-CD3 (clone OKT3)	BioLegend	Cat# 317334
Anti-CD8 (clone SK1)	BD Biosciences	Cat# 557834
Anti-CD56 (clone HCD56)	BioLegend	Cat# 318304
Chemicals, Peptides, and Recombinant Proteins		
Fixable viability dye eFluor660	eBioscience	Cat# 65-0864
FcR blocking reagent	Meltenyi Biotec,	Cat# 130-059-901
Ficoll-Hypaque gradient	GE Healthcare	Cat# 17144002
Goat anti-human IgM/HRP	Biosynthesis	Cat#bs-0345G-
Goat anti-human IgG(biotin)	Sino Biological	Cat# SSA009
HRP Mcab mouse anti-human IgG1	Cellwaylab	Cat# C030248
HRP Mcab mouse anti-human IgG2	Cellwaylab	Cat# C030245
HRP Mcab mouse anti-human IgG3	Cellwaylab	Cat# C030246
TMB substrate	Invitrogen	Cat# 00-4201-56
Mouse anti-His monoclonal antibody	Proteintech	Cat# HRP-66005
Recombinant His-tagged NP of SARS-CoV-2	In-house	N/A
Recombinant His-tagged S-RBD of SARS-	In-house	N/A
Critical Commercial Assays		
Fixation/Permeabilization Solution Kit	BD Biosciences	Cat# 554714
Human IFN- γ ELISpot ^{PRO} kit	MABTECH	Cat# 3420-2AST-
Biological Samples		
Human AB serum	GemCell	Cat# 100-512
Sera from HD#1-9	In-house	N/A
Blood samples from HD#10-14	Institute of Microbiology and Epidemiology	N/A
convalescent samples from COVID-19 patients	ChuiYangLiu Hospital	N/A
Blood samples from severe COVID-19 patients	Ditan Hospital	N/A
Deposited Data		
N/A	N/A	N/A
Experimental Models: Organisms/Strains		
HuH-7 Cells	Nie et al., 2020	N/A
Software and Algorithms		

FlowJo software v10.7	FlowJo LLC	https://www.flowjo.com/ ;RRID:SCR_008520
-----------------------	------------	--

1

2 **RESOURCE AVAILABILITY**

3 ***Lead Contact***

4 Further information and requests for resources and reagents should be directed to
5 and will be fulfilled by the lead contact, Chen Dong (chendong@tsinghua.edu.cn)

6 ***Materials Availability***

7 The plasmids (pET28-N-6XHis and pEF1a-S-RBD-6His) generated in this study will
8 be made available on request from the Lead Contact without restriction.

9 ***Data and Code Availability***

10 The study did not generate any unique dataset or code.

11

12 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

13 **COVID-19 patient blood samples**

14 The blood samples of severe COVID-19 patients defined as severe lower
15 respiratory tract infection or pneumonia with fever plus any one of the following:
16 tachypnea, respiratory distress, or oxygen saturation less than 93% on room air
17 according to the guidelines released by the national Health Commission of China
18 were obtained from Ditan hospital in Beijing. All procedures followed were in
19 accordance with the ethical standards of the responsible committee on human
20 experimentation (the institutional review board at Tsinghua University and at Ditan
21 hospital) and with the Helsinki Declaration of 1975, as revised in 2000. All studies
22 were approved by the Medical Ethical Committee at Tsinghua University. Informed
23 consent was obtained from all subjects for being included in the study. All patient

1 data were anonymized before study inclusion. See Table 1 for full patient information,
2 including age, sex, and health status.

3

4 Cell Lines

5 HuH-7 cells originally taken from a liver tumor in a Japanese male were cultured in
6 DMEM supplemented with 10% FBS. Cells were grown at 37 °C in a 5% CO₂ setting.

7

8 **METHOD DETAILS**

9 **Expression and Purification of recombinant proteins**

10 The recombinant His-tagged NP of SARS-CoV-2 was expressed in *E. coli* by a T7
11 expression system, with 1 mM IPTG induction at 37 °C for 4 h. The recombinant His-
12 tagged S-RBD (amino acids 319-541) was expressed by a mammalian system in
13 293F cells. Purified proteins were identified by SDS-PAGE gels and stained with
14 Coomassie blue.

15

16 **Isolation of PBMC**

17 PBMCs were isolated from anti-coagulant blood using Ficoll-Hypaque gradients (GE
18 Healthcare Life Sciences, Philadelphia, PA) as previously described (Xie et al., 2018)
19 under the biosafety level 3 facility in AMMS. To isolate PBMCs, blood diluted with
20 PBS, was gently layered over an equal volume of Ficoll in a Falcon tube and
21 centrifuged for 30-40 minutes at 400-500 g without brake. Four layers formed, each
22 containing different cell types. The second layer contained PBMCs. These cells
23 could be gently removed using a Pasteur pipette and added to warm medium or PBS
24 to wash off any remaining platelets. The pelleted cells were then counted and the

1 percentage viability was estimated using Trypan blue staining. Cells were then
2 cryopreserved for future study.

3

4 **Anti-SARS-CoV-2 IgG/IgM ELISA**

5 For IgM/IgG testing, 96-well ELISA plates were coated overnight with recombinant
6 NP and S-RBD (100 ng/well). The sera from COVID-19 patients were incubated for 1
7 h at 37°C. An anti-Human IgG-biotin conjugated monoclonal antibody (Cat. SSA009,
8 Sino Biological Inc., Wayne, PA) and streptavidin-HRP were used at a dilution of 1:
9 5000 and 1:250, respectively, and anti-human IgM-HRP conjugated monoclonal
10 antibody (Cat. bs-0345G-HRP, Biosynthesis Biotechnology Inc. Beijing, China) was
11 used. The OD value at 450 nm was calculated. The area under the curve (AUC) was
12 calculated by Prism 8 (Graphpad). As a second analytical approach (Grifoni et al.,
13 2020), the serum from one convalescent mild COVID-19 patient was used as a
14 positive control standard. In order to quantify the amount of anti-NP/S-RBD IgG or
15 anti-NP/S-RBD IgM present in each specimen, the positive control standard was run
16 on each plate to calculate antibody titers (relative units) for all samples using non-
17 linear regression interpolations.

18

19 **Anti-SARS-CoV-2 IgG1/IgG3 ELISA**

20 For IgG1/IgG2/IgG3 test, 96 well ELISA plates were coated (80 ng/well) overnight
21 with recombinant NP and S-RBD. Plates were washed and the sera from COVID-19
22 patients were incubated for 1 h at 37°C. After washing, an anti-Human IgG1-HRP
23 conjugated monoclonal antibody (Cat. C030248, BaiaoTong Experiment Center, LY),
24 and an anti-human IgG3-HRP conjugated monoclonal antibody (Cat.C030246,
25 BaiaoTong Experiment Center, LY), all validated by the company for their specificity,

1 were used at a dilution of 1:4000 for 1 h at RT. After washing, TMB substrate
2 solution was added. The OD value at 450 nm was calculated. The area under the
3 curve (AUC) was calculated by Prism 8 (Graphpad).

4

5 **Neutralizing antibody assay**

6 Pseudovirus expressing the SARS-CoV-2 S protein was produced. pNL43Luci and
7 GP-pCAGGS were co-transfected into 293T cells. 48 hours later, SARS-CoV-2
8 pseudovirus-containing supernatants were mixed with at least 6 serially diluted
9 serum samples from the COVID-19 patients at 37°C for 1 hour. Then the mixtures
10 were transferred to 96-well plates containing monolayers of Huh-7 cells (Nie et al.,
11 2020). 3 hours later, the medium was replaced. After incubation for 48 h, the cells
12 were washed, harvested in lysis buffer and analyzed for luciferase activity by the
13 addition of luciferase substrate. Inhibition rate = $[1 - (\text{the sample group} - \text{the cell control group}) / (\text{the virus control group} - \text{the cell control group})] \times 100\%$. The neutralizing
14 antibody titer (NAT50) were calculated by performing S-fit analysis via Graphpad
15 Prism 7 software.

16

17 **Interferon Gamma (IFN γ) ELISpot**

18 IFN- γ -secreting T cells were detected by Human IFN γ ELISpot^{PRO} kits (MABTECH AB,
19 Sweden) according to the manufacture protocol. Fresh PBMCs were plated in
20 duplicate at 150k per well and then incubated 48h with 1uM of recombinant proteins.
21 Spots were then counted using an AID ELISpot Reader System (iSpot, AID GmbH).
22 The number of spots was converted into the number of spots per million cells and
23 the mean of duplicate wells plotted.

24

25

1 **FACS staining**

2 PBMCs were washed with PBS plus 2% FBS (Gibco, Grand Island, NY), and then Fc
3 blocking reagent (Molten Biotec, Inc., Auburn, CA) was added followed by a wash
4 with PBS plus 2% FBS. Cells were then incubated for 30 min on ice with anti-CD3
5 (OKT3) (BioLegend), anti-CD8 (SK1) (BD), anti-CD56 (HCD56) (BioLegend) and
6 live/dead fixable aqua dye (eF660, eBioscience), washed twice with PBS plus 2%
7 FBS and then stored at 4 °C until acquired by FACS Verse (BD Biosciences, San
8 Jose, CA). Data were analyzed using FlowJo software (Version 10.0.8, Tree Star
9 Inc., Ashland, Or).

10

11 **QUANTIFICATION AND STATISTICAL ANALYSIS**

12 Prism 8 software is used for statistical analysis. Student's t test was performed for
13 two-group analysis. Pearson's correlation coefficients were calculated. *P* values less
14 than 0.05 were considered to be statistically significant.

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

1
2
3
4
5
6
7
8














Table 1 Clinical and pathological characteristics of the severe COVID-19 patients

Pt#	Sex	Age	Fever	Fatigue	ARDS	Lymphocyte Count	Days in hospital	Sampling day post onset	BT NA test	Discharge CT scan	Discharge NA test
#1	F	69	yes	no	yes	0.65X10 ⁹ /L	43	13	P	improvement	N
#2	M	55	yes	no	yes	1.24X10 ⁹ /L	27	18	P	improvement	N
#3	M	37	yes	no	yes	0.53X10 ⁹ /L	47	19	P	improvement	N
#4	M	52	yes	no	yes	0.94X10 ⁹ /L	39	8	P	improvement	N
#5	F	58	yes	no	yes	0.78X10 ⁹ /L	50	12	P	improvement	N
#6	M	40	yes	no	yes	1.13X10 ⁹ /L	51	11	P	improvement	N
#7	F	70	yes	no	yes	0.75X10 ⁹ /L	36	11	P	improvement	N
#8	F	66	yes	Yes	yes	0.69X10 ⁹ /L	43	2	P	improvement	N
#9	M	66	yes	No	yes	0.92X10 ⁹ /L	82	4	P	NA	NA
#10	F	62	yes	yes	yes	0.26X10 ⁹ /L	43	16	P	improvement	N

9
10
11
12
13
14


Notes: pt, patient; F, female; M, male; ARDS, acute respiratory distress syndrome; P, positive; N, negative; BT, before treatment; NA, nucleic acid; NA, non-available.

D




medRxiv preprint doi: <https://doi.org/10.1101/2020.08.10.20171371>; this version posted August 12, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


A




B






C




D






n live CD3⁺CD56⁻CD8⁻






C

Gated on live CD3⁺CD56⁻CD8⁻




E


Gated on live CD3⁺CD56⁻CD8⁻




D




F



H



A



B

